Breast cancer, a mechanism to bypass anti-ER and anti-HER2 resistance
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study
Day: November 17, 2022